Proteomics International Laboratories Ltd ABN 78 169 979 971 Box 3008, Broadway, Nedlands, WA 6009, Australia T: +61 8 9389 1992 | E: [email protected] | W: www.proteomicsinternational.com 1/4 Part of the PILL Group ASX Release 13 October...
PromarkerEndo Validation and Refinement Complete
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Proteomics International Laboratories Ltd. has completed the refinement and independent validation of its Promarker®Endo blood test for endometriosis, which is designed to aid in the clinical assessment of patients with suspected endometriosis. The company anticipates making Promarker®Endo commercially available in the third quarter of the upcoming fiscal year, pending regulatory requirements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Proteomics International Laboratories Ltd. on 6ix
In the deck
Earlier from Proteomics International Laboratories
- PromarkerD and PromarkerEso Commercial Rollout Update
- Appendix 4E and Annual Report
- Australian patent for PromarkerEndo
- Proteomics signs national distribution deal with Healius
- US patent secured for PromarkerEndo
Later from Proteomics International Laboratories
- Proteomics International receives $2.0m in R&D tax incentive
- National Rollout of PromarkerD and PromarkerEso
- Quarterly Activities/Appendix 4C Cash Flow Report
- Proteomics International Launches Share Purchase Plan
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories